✦ LIBER ✦
The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer
✍ Scribed by Adams M.; Navabi H.; Croston D.; Coleman S.; Tabi Z.; Clayton A.; Jasani B.; Mason M.D.
- Book ID
- 116957838
- Publisher
- Elsevier Science
- Year
- 2005
- Tongue
- English
- Weight
- 76 KB
- Volume
- 23
- Category
- Article
- ISSN
- 0264-410X
No coin nor oath required. For personal study only.